Jefferies Group LLC restated their buy rating on shares of Celgene Corporation (NASDAQ:CELG) in a research note published on Monday, October 16th. Jefferies Group LLC currently has a $160.00 price objective on the biopharmaceutical company’s stock.
Other research analysts have also issued reports about the stock. Zacks Investment Research upgraded shares of Celgene Corporation from a hold rating to a buy rating and set a $151.00 target price on the stock in a report on Tuesday, July 18th. SunTrust Banks, Inc. restated a buy rating and issued a $150.00 target price on shares of Celgene Corporation in a report on Friday, July 14th. Vetr downgraded shares of Celgene Corporation from a strong-buy rating to a buy rating and set a $149.76 price objective for the company. in a research note on Friday, July 14th. Bank of America Corporation reaffirmed a buy rating and set a $153.00 price objective on shares of Celgene Corporation in a research note on Monday, July 10th. Finally, Credit Suisse Group set a $148.00 price objective on shares of Celgene Corporation and gave the company a buy rating in a research note on Thursday, July 6th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, nineteen have issued a buy rating and two have given a strong buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $141.44.
Shares of Celgene Corporation (NASDAQ:CELG) traded down 1.82% during midday trading on Monday, reaching $98.17. 24,135,277 shares of the company traded hands. Celgene Corporation has a 1-year low of $94.55 and a 1-year high of $147.17. The company has a market capitalization of $76.80 billion, a PE ratio of 30.40 and a beta of 1.88. The company has a 50 day moving average price of $137.98 and a 200 day moving average price of $130.18.
Celgene Corporation (NASDAQ:CELG) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.87 by $0.04. The company had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. Celgene Corporation had a net margin of 27.36% and a return on equity of 68.62%. The firm’s quarterly revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the firm earned $1.58 EPS. On average, analysts expect that Celgene Corporation will post $7.32 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This news story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was stolen and republished in violation of international copyright and trademark laws. The original version of this news story can be read at https://www.dispatchtribunal.com/2017/10/28/celgene-corporation-celg-earns-buy-rating-from-jefferies-group-llc-2.html.
In related news, insider Terrie Curran sold 1,727 shares of Celgene Corporation stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the transaction, the insider now directly owns 3,925 shares of the company’s stock, valued at $564,768.25. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Gilla Kaplan sold 9,250 shares of the stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the completion of the transaction, the director now owns 85,551 shares of the company’s stock, valued at approximately $12,110,599.56. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 46,233 shares of company stock worth $6,268,259. 0.95% of the stock is owned by corporate insiders.
Several large investors have recently added to or reduced their stakes in CELG. Waldron LP boosted its position in shares of Celgene Corporation by 48.9% in the 1st quarter. Waldron LP now owns 5,207 shares of the biopharmaceutical company’s stock valued at $640,000 after purchasing an additional 1,709 shares during the period. Geneva Advisors LLC boosted its position in Celgene Corporation by 4.6% during the 1st quarter. Geneva Advisors LLC now owns 949,845 shares of the biopharmaceutical company’s stock worth $118,189,000 after acquiring an additional 41,500 shares during the period. Millie Capital Management LLC boosted its position in Celgene Corporation by 0.4% during the 1st quarter. Millie Capital Management LLC now owns 30,670 shares of the biopharmaceutical company’s stock worth $3,816,000 after acquiring an additional 136 shares during the period. Willingdon Wealth Management boosted its position in Celgene Corporation by 3.0% during the 1st quarter. Willingdon Wealth Management now owns 9,114 shares of the biopharmaceutical company’s stock worth $1,134,000 after acquiring an additional 268 shares during the period. Finally, Shaker Investments LLC OH boosted its position in Celgene Corporation by 140.3% during the 1st quarter. Shaker Investments LLC OH now owns 15,131 shares of the biopharmaceutical company’s stock worth $1,883,000 after acquiring an additional 8,835 shares during the period. Institutional investors and hedge funds own 79.23% of the company’s stock.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.